Chemours (CC) said Wednesday that it now expects fiscal Q2 net sales to reach the high end of its previously announced forecast of a low to mid-teens sequential increase.
Analysts polled by FactSet expect a fiscal Q2 net sales of $1.56 billion.
The company also said it now expects fiscal Q2 adjusted EBITDA of $215 million to $225 million as adjusted EBITDA from its Titanium Technologies segment is estimated to decline by about 15% sequentially due to operational disruptions at certain US sites.
Chemours previously estimated a 40% to 45% increase in fiscal Q2 adjusted EBITDA.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。